Navigation Links
Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients
Date:2/28/2011

upon receipt of required regulatory approval and adequate financing.

Dr. Charles Dinarello, Omni Bio's Director of Medical Affairs and Chief Scientific Officer commented, "Whereas we are well into the infusion stage on our first human clinical trial of Alpha-1 antitrypsin ("AAT") in Type 1 diabetes, it is essential that we establish the foundation for pursuing the commercialization of other significant areas of our intellectual property.  Over the past six months, we have initiated discussions and provided data to leading researchers and international investigators related to our intellectual property, and are pleased to advise our shareholders that we are planning substantive programs to investigate and prove AAT's effectiveness in treating additional disease classifications."  Dr. Crapo further added, "Dr. Dinarello's own work and that of his collaborators in the fields of transplantation and GVHD are widely recognized and offer Omni Bio potential new and large markets for AAT alternative use.  While in Europe over the past several months, Charles has devoted considerable time in building key strategic relationships for Omni Bio with internationally-renowned scientists."

There is no assurance that the letters of intent will lead to the commencement of actual trials or that Omni Bio will receive regulatory approvals or be able to raise additional capital on acceptable terms or at all.

Letters of intent for human clinical trials

  • The treatment of Graft vs. Host Disease in bone marrow transplant patients.  Proposed Trial Site:  University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.  Principal Investigator:  Pavan Reddy, MD, Associate Professor of Internal Medicine, Co-Director, BMT Leukemia/Lymphoma.
  • Two separate human clinical trials for the treatment of transplant rejection in kidney transplant recipients.  Proposed Trial Site:  Radboud University, Nijmegen M
    '/>"/>

  • SOURCE Omni Bio Pharmaceutical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... YORK , July 25, 2014  Smile Train ... to showcase their Virtual Surgery Simulator among leading ... which will take place in Washington, D.C. ... the Performing Arts. "Smile Train is ... alongside the talented community of innovators in health and ...
    (Date:7/25/2014)... 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased ... ("MOU") with LaurelCo, LLC, an Illinois ... cultivation and dispensary medical marijuana licenses in the state of ... will acquire a 20% equity interest in LaurelCo, LLC in ... growing chambers, as well as all technology related to the ...
    (Date:7/25/2014)...  Solanbridge Group Inc (OTC: SLNX) is pleased to ... Buzznbrewz.com and the Letter of Intent issued on July ... Purchase Agreement. Charles R. Shirley , ... have Mr. David Pecoraro and Buzznbrewz.com join ... private sector and developed a tremendous network of contacts ...
    Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
    ... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for life science companies, today announced that Kevin Hrusovsky, President ... BioConference Live event, which was held on October 26, and ... Forum on October 27 held at Harvard Medical School. ...
    ... Conn., Nov. 7, 2011 Boehringer Ingelheim Pharmaceuticals, Inc. ... a Phase 2b study, SOUND-C2, that showed the combination ... compounds – the protease inhibitor BI 201335 and the ... successful in reducing viral load below the lower limit ...
    Cached Medicine Technology:Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 3Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 4Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 5
    (Date:7/28/2014)... July 28, 2014 According to court documents, ... owner of The Marcal Group (TMG), met with ... (HMG). A contract, as well a broad project outline, were ... as well as branding services and marketing. , ... by HMG throughout the course of the project, praise was ...
    (Date:7/28/2014)... Downers Grove, IL (PRWEB) July 28, 2014 ... marketing company for mental health professionals, announced today its ... Family Therapy (IAMFT). This new relationship allows TherapySites ... IAMFT members, adding exclusive benefits and promotional offers. , ... business is being done today. With nearly 3 ...
    (Date:7/28/2014)... July 28, 2014 According to the Heartburn ... a comprehensive guide that will help people get rid of ... all the necessary information about heartburn and acid reflux. In ... about heartburn , and risk factors for reflux disease. ... help people get rid of symptoms of reflux disease naturally ...
    (Date:7/28/2014)... July 28, 2014 Shore Points Capital ... its investment in Loftware, Inc., through a recapitalization of ... Points was the lead investor in Loftware for over ... become the leading international provider of enterprise level software ... been a great investment for us, and we are ...
    (Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
    Breaking Medicine News(10 mins):Health News:Calko Medical Center Loses Website Twice over Non-Payment, According to Court Documents 2Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2
    ... over past 20 years due to suffocation, strangulation , ... accidental injury or death associated with crib bumper pads ... University School of Medicine in St. Louis. , Many ... protect babies from injury. But the researchers reviewed U.S. ...
    ... 2007 Late-breaking results from the ENDEAVOR IV trial, ... the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting ... overall safety profile (equivalent rates of death, heart attack, ... 1 year. , In addition, the Endeavor stent ...
    ... Lack Proper Healthcare Coverage, SAN FRANCISCO, ... Chapter of Autism Speaks today announced the ... Commission on,Autism,s recommendations to ensure appropriate and ... These recommendations were,finalized and presented to the ...
    ... MINNEAPOLIS, Oct. 22 Building upon its impressive ... laying out,a global vision, which will propel it ... orthopaedic research, education and new product,innovation, will solidify ... Over the next year, MORF will be ...
    ... than 450 people gathered on,Tuesday, October 9, at The ... 18th Annual CATCH Night of Champions. The event,featured a ... ceremony. The,event raised $225,000, with more than $38,000 raised ... been a major supporter of the charity since,1989, and ...
    ... has significantly increased life expectancy in early tests of ... most aggressive form of brain cancer in adults − ... Mayo Clinic in Jacksonville. , The vaccine represents a ... says neurosurgeon Kent New, M.D., Ph.D., who will be ...
    Cached Medicine News:Health News:Crib Bumper Pads Too Risky for Baby 2Health News:ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 3Health News:Mayo Clinic tests novel vaccine for aggressive brain tumors 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: